Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
Lancet
    April 2024
  1. HOI A, Igel T, Mok CC, Arnaud L, et al
    Systemic lupus erythematosus.
    Lancet. 2024 Apr 17:S0140-6736(24)00398-2. doi: 10.1016/S0140-6736(24)00398.
    >> Share

  2. KRICKAU T, Naumann-Bartsch N, Aigner M, Kharboutli S, et al
    CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis.
    Lancet. 2024 Apr 17:S0140-6736(24)00424-0. doi: 10.1016/S0140-6736(24)00424.
    >> Share

    February 2024
  3. KRONBICHLER A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, et al
    Diagnosis and management of ANCA-associated vasculitis.
    Lancet. 2024;403:683-698.
    >> Share

  4. VAN DER HELM-VAN MIL AHM
    Abatacept in individuals with autoantibody-positive arthralgia at risk for rheumatoid arthritis.
    Lancet. 2024 Feb 14:S0140-6736(24)00055-2. doi: 10.1016/S0140-6736(24)00055.
    >> Share

    January 2024
  5. WEST EE, Woodruff T, Fremeaux-Bacchi V, Kemper C, et al
    Complement in human disease: approved and up-and-coming therapeutics.
    Lancet. 2024;403:392-405.
    >> Share

  6. CHAKER L, Cooper DS, Walsh JP, Peeters RP, et al
    Hyperthyroidism.
    Lancet. 2024 Jan 23:S0140-6736(23)02016-0. doi: 10.1016/S0140-6736(23)02016.
    >> Share

    November 2023
  7. JAKIMOVSKI D, Bittner S, Zivadinov R, Morrow SA, et al
    Multiple sclerosis.
    Lancet. 2023 Nov 7:S0140-6736(23)01473-3. doi: 10.1016/S0140-6736(23)01473.
    >> Share

  8. REICH HN, Barbour SJ
    PROTECTing the kidneys in IgA nephropathy.
    Lancet. 2023 Nov 3:S0140-6736(23)02418-2. doi: 10.1016/S0140-6736(23)02418.
    >> Share

  9. ROVIN BH, Barratt J, Heerspink HJL, Alpers CE, et al
    Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Lancet. 2023 Nov 2:S0140-6736(23)02302-4. doi: 10.1016/S0140-6736(23)02302.
    >> Share

  10. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    >> Share

    October 2023
  11. ESPIGOL-FRIGOLE G, Dejaco C, Mackie SL, Salvarani C, et al
    Polymyalgia rheumatica.
    Lancet. 2023;402:1459-1472.
    >> Share

  12. RUSSELL-JONES D, Babazono T, Cailleteau R, Engberg S, et al
    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
    Lancet. 2023 Oct 17:S0140-6736(23)02179-7. doi: 10.1016/S0140-6736(23)02179.
    >> Share

  13. SHAH AS, Wolf RM
    Weekly insulin: a paradigm shift in type 1 diabetes therapy.
    Lancet. 2023 Oct 17:S0140-6736(23)02227-4. doi: 10.1016/S0140-6736(23)02227.
    >> Share

    September 2023
  14. BROOME CM, McDonald V, Miyakawa Y, Carpenedo M, et al
    Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2023 Sep 28:S0140-6736(23)01460-5. doi: 10.1016/S0140-6736(23)01460.
    >> Share

  15. MAHAMAD S, Arnold DM
    Inhibition of neonatal Fc receptor as a treatment for immune thrombocytopenia.
    Lancet. 2023 Sep 28:S0140-6736(23)01836-6. doi: 10.1016/S0140-6736(23)01836.
    >> Share

  16. SCHETT G, Mackensen A, Mougiakakos D
    CAR T-cell therapy in autoimmune diseases.
    Lancet. 2023 Sep 22:S0140-6736(23)01126-1. doi: 10.1016/S0140-6736(23)01126.
    >> Share

    August 2023
  17. LAFAYETTE R, Kristensen J, Stone A, Floege J, et al
    Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
    Lancet. 2023 Aug 14:S0140-6736(23)01554-4. doi: 10.1016/S0140-6736(23)01554.
    >> Share

  18. HARALDSSON B
    Phase 3 trial results bring hope for patients with IgA nephropathy.
    Lancet. 2023 Aug 14:S0140-6736(23)01633-1. doi: 10.1016/S0140-6736(23)01633.
    >> Share

  19. RAMANAN AV, Quartier P, Okamoto N, Foeldvari I, et al
    Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Lancet. 2023;402:555-570.
    >> Share

    July 2023
  20. RIFE EC, Cron RQ
    Janus kinase inhibition in juvenile idiopathic arthritis.
    Lancet. 2023 Jul 6:S0140-6736(23)01134-0. doi: 10.1016/S0140-6736(23)01134.
    >> Share

    June 2023

  21. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2023 Jun 22:S0140-6736(23)01301-6. doi: 10.1016/S0140-6736(23)01301.
    >> Share

  22. DAVIES MJ, Ahmad E, Lim S, Lamptey R, et al
    Cancer is becoming the leading cause of death in diabetes - Authors' reply.
    Lancet. 2023;401:1849-1850.
    >> Share

    May 2023
  23. CONRAD N, Misra S, Verbakel JY, Verbeke G, et al
    Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
    Lancet. 2023 May 5:S0140-6736(23)00457-9. doi: 10.1016/S0140-6736(23)00457.
    >> Share

  24. WEN X, Li B
    A population-based study on autoimmune disease.
    Lancet. 2023 May 5:S0140-6736(23)00621-9. doi: 10.1016/S0140-6736(23)00621.
    >> Share

    April 2023
  25. QUATTRIN T, Mastrandrea LD, Walker LSK
    Type 1 diabetes.
    Lancet. 2023 Apr 5:S0140-6736(23)00223-4. doi: 10.1016/S0140-6736(23)00223.
    >> Share

    March 2023
  26. LUNDBERG S, Bergen K
    We can go further in non-immunosuppressive treatment of IgA nephropathy.
    Lancet. 2023 Mar 31:S0140-6736(23)00630-X. doi: 10.1016/S0140-6736(23)00630.
    >> Share

  27. HEERSPINK HJL, Radhakrishnan J, Alpers CE, Barratt J, et al
    Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
    Lancet. 2023 Mar 31:S0140-6736(23)00569-X. doi: 10.1016/S0140-6736(23)00569.
    >> Share

  28. DURCAN L, Murphy G
    SLE-BRAVE I and II.
    Lancet. 2023;401:972-973.
    >> Share

  29. GREGG EW, Buckley J, Ali MK, Davies J, et al
    Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact.
    Lancet. 2023 Mar 14:S0140-6736(23)00001-6. doi: 10.1016/S0140-6736(23)00001.
    >> Share

    February 2023
  30. PETRI M, Bruce IN, Dorner T, Tanaka Y, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
    Lancet. 2023 Feb 24:S0140-6736(22)02546-6. doi: 10.1016/S0140-6736(22)02546.
    >> Share

  31. MORAND EF, Vital EM, Petri M, van Vollenhoven R, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
    Lancet. 2023 Feb 24:S0140-6736(22)02607-1. doi: 10.1016/S0140-6736(22)02607.
    >> Share

    January 2023
  32. VOLKMANN ER, Andreasson K, Smith V
    Systemic sclerosis.
    Lancet. 2023;401:304-318.
    >> Share

  33. GUGER M, Ransmayr G, Sonnberger M, Hametner S, et al
    Tumefactive multiple sclerosis presents with painless progressive hemiparesis and aphasia.
    Lancet. 2023;401:226.
    >> Share

  34. CONRAD N, McMurray JJV
    Cardiovascular risk in systemic autoimmune diseases - Authors' reply.
    Lancet. 2023;401:22.
    >> Share

  35. FUNADA S, Luo Y, Nishioka N, Yoshioka T, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21.
    >> Share

  36. CAFARO G, Perricone C, Gerli R, Bartoloni E, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21-22.
    >> Share

    December 2022
  37. HEBBINK JA, Nobels-Janssen E, Verhagen I, Kusters B, et al
    Subacute parkinsonism due to systemic lupus erythematosus and catastrophic antiphospholipid syndrome.
    Lancet. 2022;400:1966.
    >> Share

    October 2022
  38. WIECH T, Reinhard L, Wulf S, Giuffrida AE, et al
    Bacterial infection possibly causing autoimmunity: Tropheryma whipplei and membranous nephropathy.
    Lancet. 2022 Oct 31. pii: S0140-6736(22)02039.
    >> Share

    August 2022
  39. RIDKER PM
    Autoimmune diseases and atherothrombotic risk.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01602.
    >> Share

  40. CONRAD N, Verbeke G, Molenberghs G, Goetschalckx L, et al
    Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01349.
    >> Share

    May 2022
  41. RUPERTO N, Brunner HI, Posner HB, Lazariciu I, et al
    Tofacitinib for juvenile idiopathic arthritis - Authors' reply.
    Lancet. 2022;399:1866.
    >> Share

  42. MURRAY GM, Renton WD
    Tofacitinib for juvenile idiopathic arthritis.
    Lancet. 2022;399:1865-1866.
    >> Share

    April 2022
  43. SETHI S, De Vriese AS, Fervenza FC
    Acute glomerulonephritis.
    Lancet. 2022;399:1646-1663.
    >> Share

  44. PRASAD A
    Angela Migowa: advocating for children with rheumatic diseases.
    Lancet. 2022;399:1294.
    >> Share

    March 2022
  45. YAKOVENKO V, Brauner R, Votinov E, Goldfarb Y, et al
    Infective endocarditis and thromboses due to antiphospholipid syndrome following acute Q fever.
    Lancet. 2022;399:1154.
    >> Share

    January 2022
  46. KAMOI K, Uchimaru K, Tojo A, Watanabe T, et al
    HTLV-1 uveitis and Graves' disease presenting with sudden onset of blurred vision.
    Lancet. 2022;399:60.
    >> Share

    November 2021
  47. CLARKE SLN, Ramanan AV
    Tofacitinib in juvenile idiopathic arthritis.
    Lancet. 2021;398:1943-1945.
    >> Share

  48. RUPERTO N, Brunner HI, Synoverska O, Ting TV, et al
    Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
    Lancet. 2021;398:1984-1996.
    >> Share

  49. LODGE FM, Moody WE, Tosounidou S, Chue CD, et al
    Hydroxychloroquine-induced cardiomyopathy accelerated after gastric banding.
    Lancet. 2021;398:1913.
    >> Share

  50. BHUTTA ZA, Salam RA, Gomber A, Lewis-Watts L, et al
    A century past the discovery of insulin: global progress and challenges for type 1 diabetes among children and adolescents in low-income and middle-income countries.
    Lancet. 2021;398:1837-1850.
    >> Share

  51. HELLER SR, Durrant A, Tandon N
    Insulin, the patient, and the health professional.
    Lancet. 2021;398:1785-1786.
    >> Share

  52. THE LANCET
    100 years of insulin: a technical success but an access failure.
    Lancet. 2021;398:1777.
    >> Share

  53. DEVI S
    Cold comfort: getting insulin to those who need it.
    Lancet. 2021;398:1791.
    >> Share

    October 2021
  54. CHEN LYC, Slack GW, Carruthers MN
    IgG4-related disease and Rosai-Dorfman-Destombes disease.
    Lancet. 2021;398:1213-1214.
    >> Share

  55. EMILE JF, Vaglio A, Cohen-Aubart F, Haroche J, et al
    IgG4-related disease and Rosai-Dorfman-Destombes disease - Authors' reply.
    Lancet. 2021;398:1214-1215.
    >> Share

    August 2021
  56. PERRY RJ, Tamborska A, Singh B, Craven B, et al
    Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01608.
    >> Share

    July 2021
  57. RAMSPOTT JP, Neureiter D, Emmanuel K, Jager T, et al
    Granulomatosis with polyangiitis presents with skip lesions of the bowel.
    Lancet. 2021;398:e8.
    >> Share

  58. HAWKINS P, Chawke L, Cormican L, Wikenheiser-Brokamp KA, et al
    Autoimmune pulmonary alveolar proteinosis: a discrepancy between symptoms and CT findings.
    Lancet. 2021;398:e7.
    >> Share

    June 2021
  59. MCGINLEY MP, Cohen JA
    Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    Lancet. 2021 Jun 24. pii: S0140-6736(21)00244.
    >> Share

  60. NORGAARD K, Schmidt S
    Is reimbursement for alerts and real-time continuous glucose monitoring needed?
    Lancet. 2021;397:2230-2232.
    >> Share

  61. TSAGKAS C, Schafer S, Baumgartner A, Muller J, et al
    Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica.
    Lancet. 2021;397:2194.
    >> Share

  62. VISSER MM, Charleer S, Fieuws S, De Block C, et al
    Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.
    Lancet. 2021 Jun 1. pii: S0140-6736(21)00789.
    >> Share

    May 2021
  63. ROVIN BH, Teng YKO, Ginzler EM, Arriens C, et al
    Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet. 2021 May 7. pii: S0140-6736(21)00578.
    >> Share

  64. MOK CC
    A new old treatment for lupus nephritis.
    Lancet. 2021 May 7. pii: S0140-6736(21)00663.
    >> Share

    April 2021
  65. BAYAS A, Menacher M, Christ M, Behrens L, et al
    Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00872.
    >> Share

  66. MIZELLE RM JR
    Diabetes, race, and amputations.
    Lancet. 2021;397:1256-1257.
    >> Share

    October 2020
  67. HABIB SM, Vermeer MH
    A baby with red plaques on the face and a first-degree heart block: neonatal lupus.
    Lancet. 2020;396:1432.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016